Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1981 1
1986 1
1992 1
1997 2
2006 1
2007 1
2008 2
2010 3
2011 1
2012 2
2013 3
2014 2
2015 2
2016 2
2017 2
2018 2
2019 1
2020 5
2021 2
2022 1
2024 1
2025 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for feser j[au]
Your search for Feeser J[au] retrieved no results
Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 study.
Frenck RW Jr, Naficy A, Feser J, Dickey MP, Leyva-Grado VH, Egan MA, Chen T, Eldridge JH, Sciotto-Brown S, Hermida L, Promeneur D, Luckay A, Medina H, Lazaro GA, Patel NR, Naqvi T, Broder CC, Dimitrov AS, Gast C, Mercer LD, Raine M, Andi-Lolo I, Innis BL, Aponte JJ, Hamm S, Rathi N. Frenck RW Jr, et al. Among authors: feser j. Lancet. 2025 Dec 13;406(10521):2792-2803. doi: 10.1016/S0140-6736(25)01390-X. Epub 2025 Nov 14. Lancet. 2025. PMID: 41248666 Clinical Trial.
Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials.
Langley JM, Sadarangani M, Ockenhouse C, Barreto L, Ye L, Tang Y, Breeze JL, Feser J, Hosken NA, Andi-Lolo I, Tasker SA, Halperin SA; Canadian Immunization Research Network. Langley JM, et al. Among authors: feser j. Vaccine. 2026 Mar 7;75:128236. doi: 10.1016/j.vaccine.2026.128236. Epub 2026 Jan 22. Vaccine. 2026. PMID: 41576705 Free article. Clinical Trial.
Chromatin structure as a mediator of aging.
Feser J, Tyler J. Feser J, et al. FEBS Lett. 2011 Jul 7;585(13):2041-8. doi: 10.1016/j.febslet.2010.11.016. Epub 2010 Nov 16. FEBS Lett. 2011. PMID: 21081125 Free PMC article. Review.
A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein.
Bliss CM, Nachbagauer R, Mariottini C, Cuevas F, Feser J, Naficy A, Bernstein DI, Guptill J, Walter EB, Berlanda-Scorza F, Innis BL, García-Sastre A, Palese P, Krammer F, Coughlan L. Bliss CM, et al. Among authors: feser j. EBioMedicine. 2024 Jun;104:105153. doi: 10.1016/j.ebiom.2024.105153. Epub 2024 May 27. EBioMedicine. 2024. PMID: 38805853 Free PMC article. Clinical Trial.
More power to pyroelectrics.
Feser JP, Ravichandran J. Feser JP, et al. Nat Mater. 2018 May;17(5):385-386. doi: 10.1038/s41563-018-0065-x. Nat Mater. 2018. PMID: 29662158 No abstract available.
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.
Nachbagauer R, Feser J, Naficy A, Bernstein DI, Guptill J, Walter EB, Berlanda-Scorza F, Stadlbauer D, Wilson PC, Aydillo T, Behzadi MA, Bhavsar D, Bliss C, Capuano C, Carreño JM, Chromikova V, Claeys C, Coughlan L, Freyn AW, Gast C, Javier A, Jiang K, Mariottini C, McMahon M, McNeal M, Solórzano A, Strohmeier S, Sun W, Van der Wielen M, Innis BL, García-Sastre A, Palese P, Krammer F. Nachbagauer R, et al. Among authors: feser j. Nat Med. 2021 Jan;27(1):106-114. doi: 10.1038/s41591-020-1118-7. Epub 2020 Dec 7. Nat Med. 2021. PMID: 33288923 Clinical Trial.
38 results